Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 75.03 Billion KRW | 18.87% |
| 2022 | 61.97 Billion KRW | 2.72% |
| 2021 | 60.33 Billion KRW | 19.11% |
| 2020 | 50.65 Billion KRW | -19.32% |
| 2019 | 62.78 Billion KRW | 28.06% |
| 2018 | 49.02 Billion KRW | 14.87% |
| 2017 | 42.67 Billion KRW | 10.85% |
| 2016 | 38.5 Billion KRW | 4.34% |
| 2015 | 36.9 Billion KRW | -7.85% |
| 2014 | 40.04 Billion KRW | 26.12% |
| 2013 | 31.75 Billion KRW | -10.44% |
| 2012 | 35.45 Billion KRW | -20.13% |
| 2011 | 44.38 Billion KRW | -20.96% |
| 2010 | 56.15 Billion KRW | 11.67% |
| 2009 | 50.28 Billion KRW | -2.61% |
| 2008 | 51.63 Billion KRW | 8.98% |
| 2007 | 47.37 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 18.28 Billion KRW | 28.21% |
| 2024 Q2 | 15.55 Billion KRW | -14.96% |
| 2024 Q3 | 36.84 Billion KRW | 27.3% |
| 2023 Q3 | 17.54 Billion KRW | -35.49% |
| 2023 Q4 | 14.26 Billion KRW | -18.72% |
| 2023 Q2 | 27.2 Billion KRW | 73.01% |
| 2023 Q1 | 15.72 Billion KRW | -11.29% |
| 2023 FY | 73.66 Billion KRW | 18.87% |
| 2022 Q1 | 12.78 Billion KRW | -8.61% |
| 2022 Q3 | 16.52 Billion KRW | 10.57% |
| 2022 Q4 | 17.72 Billion KRW | 7.29% |
| 2022 FY | 61.97 Billion KRW | 2.72% |
| 2022 Q2 | 14.94 Billion KRW | 16.87% |
| 2021 Q1 | 17.79 Billion KRW | 44.88% |
| 2021 Q3 | 14.84 Billion KRW | 8.26% |
| 2021 Q4 | 13.98 Billion KRW | -5.74% |
| 2021 Q2 | 13.7 Billion KRW | -22.97% |
| 2021 FY | 60.33 Billion KRW | 19.11% |
| 2020 FY | 50.65 Billion KRW | -19.32% |
| 2020 Q2 | 12.78 Billion KRW | -4.86% |
| 2020 Q3 | 12.14 Billion KRW | -5.0% |
| 2020 Q1 | 13.43 Billion KRW | 1.76% |
| 2020 Q4 | 12.28 Billion KRW | 1.13% |
| 2019 FY | 62.78 Billion KRW | 28.06% |
| 2019 Q2 | 18.86 Billion KRW | 33.75% |
| 2019 Q3 | 16.6 Billion KRW | -12.0% |
| 2019 Q4 | 13.2 Billion KRW | -20.46% |
| 2019 Q1 | 14.1 Billion KRW | 12.86% |
| 2018 Q2 | 12.07 Billion KRW | -0.09% |
| 2018 FY | 49.02 Billion KRW | 14.87% |
| 2018 Q4 | 12.49 Billion KRW | 1.0% |
| 2018 Q3 | 12.37 Billion KRW | 2.51% |
| 2018 Q1 | 12.08 Billion KRW | 17.4% |
| 2017 Q1 | 9.03 Billion KRW | 8.07% |
| 2017 Q4 | 10.29 Billion KRW | -22.37% |
| 2017 FY | 42.67 Billion KRW | 10.85% |
| 2017 Q2 | 10.09 Billion KRW | 11.72% |
| 2017 Q3 | 13.25 Billion KRW | 31.32% |
| 2016 Q4 | 8.36 Billion KRW | -7.58% |
| 2016 FY | 38.5 Billion KRW | 4.34% |
| 2016 Q1 | 10.94 Billion KRW | 16.58% |
| 2016 Q2 | 10.15 Billion KRW | -7.18% |
| 2016 Q3 | 9.04 Billion KRW | -10.91% |
| 2015 Q4 | 9.38 Billion KRW | 16.57% |
| 2015 Q2 | 9.55 Billion KRW | -3.55% |
| 2015 Q3 | 8.05 Billion KRW | -15.76% |
| 2015 Q1 | 9.9 Billion KRW | -6.95% |
| 2015 FY | 36.9 Billion KRW | -7.85% |
| 2014 Q3 | 9.76 Billion KRW | -4.56% |
| 2014 FY | 40.04 Billion KRW | 26.12% |
| 2014 Q1 | 9.4 Billion KRW | 32.35% |
| 2014 Q4 | 10.64 Billion KRW | 9.07% |
| 2014 Q2 | 10.22 Billion KRW | 8.77% |
| 2013 FY | 31.75 Billion KRW | -10.44% |
| 2013 Q4 | 7.1 Billion KRW | -16.34% |
| 2013 Q3 | 8.49 Billion KRW | 2.52% |
| 2013 Q2 | 8.28 Billion KRW | 5.34% |
| 2013 Q1 | 7.86 Billion KRW | -7.04% |
| 2012 Q2 | 7.96 Billion KRW | -11.16% |
| 2012 FY | 35.45 Billion KRW | -20.13% |
| 2012 Q4 | 8.46 Billion KRW | -15.83% |
| 2012 Q3 | 10.05 Billion KRW | 26.12% |
| 2012 Q1 | 8.97 Billion KRW | 0.0% |
| 2011 Q2 | 9.74 Billion KRW | -22.65% |
| 2011 FY | 44.38 Billion KRW | -20.96% |
| 2011 Q1 | 12.59 Billion KRW | -14.04% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 10.59 Billion KRW | 8.73% |
| 2010 Q1 | 12.32 Billion KRW | -11.36% |
| 2010 FY | 56.15 Billion KRW | 11.67% |
| 2010 Q4 | 14.65 Billion KRW | 3.12% |
| 2010 Q3 | 14.21 Billion KRW | -4.98% |
| 2010 Q2 | 14.95 Billion KRW | 21.33% |
| 2009 Q2 | 13.51 Billion KRW | 13.86% |
| 2009 Q1 | 11.86 Billion KRW | -20.41% |
| 2009 Q3 | 11 Billion KRW | -18.57% |
| 2009 Q4 | 13.9 Billion KRW | 26.42% |
| 2009 FY | 50.28 Billion KRW | -2.61% |
| 2008 Q3 | 13.29 Billion KRW | 7.63% |
| 2008 Q4 | 14.9 Billion KRW | 12.16% |
| 2008 FY | 51.63 Billion KRW | 8.98% |
| 2008 Q1 | 11.08 Billion KRW | -10.29% |
| 2008 Q2 | 12.35 Billion KRW | 11.46% |
| 2007 FY | 47.37 Billion KRW | 0.0% |
| 2007 Q2 | 12.12 Billion KRW | 10.9% |
| 2007 Q3 | 11.97 Billion KRW | -1.27% |
| 2007 Q1 | 10.93 Billion KRW | 0.0% |
| 2007 Q4 | 12.35 Billion KRW | 3.18% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.358% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 79.391% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 62.27% |
| HANDOK Inc. | 151.36 Billion KRW | 50.425% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -11.625% |
| Yuhan Corporation | 564.5 Billion KRW | 86.707% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 76.711% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -215.995% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 91.022% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 62.284% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -84.601% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 20.606% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 46.726% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.358% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -116.154% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 2.316% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 722.962% |
| JW Holdings Corporation | 446.15 Billion KRW | 83.181% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 63.843% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 88.55% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.645% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 4.554% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 0.264% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -3.916% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 59.176% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -61.358% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 74.573% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 88.99% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.645% |
| Yuhan Corporation | 564.5 Billion KRW | 86.707% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 62.819% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -5.78% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 24.223% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 77.645% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 48.565% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 56.747% |
| CKD Bio Corp. | 5.01 Billion KRW | -1397.705% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 70.484% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 59.245% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 23.527% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 4.554% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 79.801% |
| Boryung Corporation | 333.26 Billion KRW | 77.484% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -49.943% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 62.284% |
| JW Lifescience Corporation | 51.32 Billion KRW | -46.205% |